Pam3CSK4 (Synonyms: Pam3Cys-Ser-(Lys)4) |
Catalog No.GC10273
One-Click Copy Product Info
|
Pam3CSK4 is a synthetic triacylated lipopeptide (LP) and a TLR2/TLR1 ligand agonist with an EC50 value of 0.47ng/ml.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 112208-00-1
Sample solution is provided at 25 µL, 10mM.
Pam3CSK4 is a synthetic triacylated lipopeptide (LP) and a TLR2/TLR1 ligand agonist with an EC50 value of 0.47ng/ml[1]. Pam3CSK4 can induce the production of IFN-inducible genes (including IFN-β, iNOS) in mouse macrophages through TRIF-independent and TBK1-dependent pathways[2]. Pam3CSK4 has been widely used to inhibit respiratory syncytial virus infection and as an adjuvant in live-attenuated viral vaccines[3].
In vitro, Pam3CSK4 (1µg/ml) treatment for 48 hours significantly induced the differentiation of glioblastoma stem cells and decreased the expression of CD133[4]. Pre-incubation of LAD2 cells with 10µg/ml Pam3CSK4 for 24 hours significantly induced the release of IL-8 and inhibited the increase of intracellular calcium ions induced by IgE antibodies[5]. Treatment with 0.5µg/ml Pam3CSK4 for 5 days significantly promoted the growth of mouse B cells and inhibited the production of IgG1 in response to lipopolysaccharide stimulation[6].
In vivo, Pam3CSK4 treatment via a single intraperitoneal injection at a dose of 1mg/kg for 24 hours reduced the myocardial infarction area in mice after myocardial ischemia/reperfusion and inhibited CXCL1-dependent leukocyte recruitment[7]. A single intraperitoneal injection of a 100µg dose of Pam3CSK4 reduced the Leptospira burden in hamsters within 4 days, increased the survival rate, and reduced kidney and lung hemorrhage[8].
References:
[1] Ozinsky A, Underhill D M, Fontenot J D, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors[J]. Proceedings of the National Academy of Sciences, 2000, 97(25): 13766-13771.
[2] Kulsantiwong P, Pudla M, Srisaowakarn C, et al. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264. 7[J]. Inflammation Research, 2017, 66(10): 843-853.
[3] Nguyen D T, de Witte L, Ludlow M, et al. The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation[J]. PLoS pathogens, 2010, 6(8): e1001049.
[4] Megías J, Martínez A, San-Miguel T, et al. Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide[J]. Investigational new drugs, 2020, 38(2): 299-310.
[5] Yu Y, Yip K H, Tam I Y S, et al. Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation[J]. PLoS One, 2014, 9(11): e112989.
[6] Lee S H, Park S R. Toll-like receptor 1/2 agonist Pam3CSK4 suppresses lipopolysaccharide-driven IgG1 production while enhancing IgG2a production by B cells[J]. Immune Network, 2018, 18(1).
[7] Mersmann J, Berkels R, Zacharowski P, et al. Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury[J]. Critical care medicine, 2010, 38(3): 903-909.
[8] Zhang W, Zhang N, Xie X, et al. Toll-like receptor 2 agonist Pam3CSK4 alleviates the pathology of leptospirosis in hamster[J]. Infection and immunity, 2016, 84(12): 3350-3357.
| Cell experiment [1]: | |
|
Cell lines |
LAD2 cells |
|
Preparation Method |
LAD2 cells were maintained in StemPro-34 medium supplemented with 10ml/l StemPro nutrient supplement, 1% penicillin- streptomycin, 2mM L-glutamine, 100ng/ml human stem cell factor, and 50ng/ml interleukin-6 in an atmosphere containing 5% CO2 at 37°C. LAD2 cells were pre-incubated with various concentrations of Pam3CSK4 (0, 0.1, 1, 10, and 100µg/ml) prior to incubation with anti-IgE (2µg/ml) for 24h to allow synthesis and release of IL-8. The release of IL-8 in the supernatants was measured by ELISA assay. |
|
Reaction Conditions |
0, 0.1, 1, 10, and 100µg/ml; 24h |
|
Applications |
Pam3CSK4 treatment enhanced IL-8 release from LAD2 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Hamsters |
|
Preparation Method |
Hamsters were housed under controlled temperature (21-23°C), humidity (30-35%), and light cycle (7:00 AM to 7:00 PM) and maintained on a standard rodent diet. Hamsters were inoculated intraperitoneally with 0.5ml of PBS containing 106 leptospires either alone or mixed with 100μg Pam3CSK4. Four days later, the kidneys and lungs of the hamsters were collected for analysis. |
|
Dosage form |
100µg; once; i.p. |
|
Applications |
Pam3CSK4 treatment alleviated tissue injury of the kidneys and lungs and decreased the abundance of leptospires in hamsters. |
References: [1] Yu Y, Yip K H, Tam I Y S, et al. Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation[J]. PLoS One, 2014, 9(11): e112989. [2] Zhang W, Zhang N, Xie X, et al. Toll-like receptor 2 agonist Pam3CSK4 alleviates the pathology of leptospirosis in hamster[J]. Infection and immunity, 2016, 84(12): 3350-3357. | |
| Cas No. | 112208-00-1 | SDF | |
| Synonyms | Pam3Cys-Ser-(Lys)4 | ||
| Chemical Name | (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17R)-2,5,8,11-tetrakis(4-aminobutyl)-4,7,10,13,16-pentahydroxy-17-((Z)-(1-hydroxyhexadecylidene)amino)-14-(hydroxymethyl)-24-oxo-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-pentaazanonatriaconta-3,6,9,12,15-pentaen-1-oi | ||
| Canonical SMILES | CCCCCCCCCCCCCCC/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](C(O)=O)([H])CCCCN)([H])CCCCN)([H])CCCCN)([H])CCCCN)([H])CO)([H])CSCC(OC(CCCCCCCCCCCCCCC)=O)([H])COC(CCCCCCCCCCCCCCC)=O | ||
| Formula | C81H156N10O13S | M.Wt | 1510.24 |
| Solubility | 50 mg/mL in DMSO ( Need ultrasonic); 16.67 mg/mL in Water ( Needultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 662.1 μL | 3.3107 mL | 6.6215 mL |
| 5 mM | 132.4 μL | 662.1 μL | 1.3243 mL |
| 10 mM | 66.2 μL | 331.1 μL | 662.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)